Contributions
Abstract: P1241
Type: Poster
Abstract Category: Therapy - disease modifying - Risk management for disease modifying treatments
Background: Alemtuzumab is one of the most promising drugs in Multiple Sclerosis. The aim is to asses if a protocols with Preventive and Infectious Unit could be useful for improving drug safety, following the example of other biologics drugs.
Methods: We collected data of 35 patients of our monographic Alemtuzumab Unit. The pre-screening included HIV, Varicella, Hepatitis, Measles, Mumps and Rubella serologies, QuantiFERON, Mantoux and chest radiography. Routine immunizations in the months prior to infusion were against pneumococcus, Haemophilus influenza, hepatitis A and B, meningoco and tetanus. Vaccination of measles, rubella, mumps and Varicella depended on the serological results. A checklist of adverse effects was applied monthly after the treatment. The second dose of vaccine as tetanus, hepatitis B or pneumococcus was measured when the drug lymphopenia is corrected.
Results: We detected 27 infections in our sample. All cases were resolved with treatment. We found 13 upper tract infections and 4 gastroenteritis and 2 patients with herpes labialis and urinary infection. We collected 3 cases of prolonged fever (all of them solved with Septrim or antibiotics). One case was reported of: fungal infection, infection cyst buccal mucosa, pneumonia, ear infections, onychomycosis and infectious cellulitis.
Conclusions: This protocol with Infectious and Preventive Unit can minimize infections incedence. Fever of unknown origin must be study properly in our patients. It must assess the prolongation of preventing with acyclovir if there are previous herpes and the need for prophylactic antibiotics in patients with recurrent respiratory infections. Futher studies to improve knowledge about immunization after vaccination are needed.
Disclosure: There are not conflict of interest and source of founding
Abstract: P1241
Type: Poster
Abstract Category: Therapy - disease modifying - Risk management for disease modifying treatments
Background: Alemtuzumab is one of the most promising drugs in Multiple Sclerosis. The aim is to asses if a protocols with Preventive and Infectious Unit could be useful for improving drug safety, following the example of other biologics drugs.
Methods: We collected data of 35 patients of our monographic Alemtuzumab Unit. The pre-screening included HIV, Varicella, Hepatitis, Measles, Mumps and Rubella serologies, QuantiFERON, Mantoux and chest radiography. Routine immunizations in the months prior to infusion were against pneumococcus, Haemophilus influenza, hepatitis A and B, meningoco and tetanus. Vaccination of measles, rubella, mumps and Varicella depended on the serological results. A checklist of adverse effects was applied monthly after the treatment. The second dose of vaccine as tetanus, hepatitis B or pneumococcus was measured when the drug lymphopenia is corrected.
Results: We detected 27 infections in our sample. All cases were resolved with treatment. We found 13 upper tract infections and 4 gastroenteritis and 2 patients with herpes labialis and urinary infection. We collected 3 cases of prolonged fever (all of them solved with Septrim or antibiotics). One case was reported of: fungal infection, infection cyst buccal mucosa, pneumonia, ear infections, onychomycosis and infectious cellulitis.
Conclusions: This protocol with Infectious and Preventive Unit can minimize infections incedence. Fever of unknown origin must be study properly in our patients. It must assess the prolongation of preventing with acyclovir if there are previous herpes and the need for prophylactic antibiotics in patients with recurrent respiratory infections. Futher studies to improve knowledge about immunization after vaccination are needed.
Disclosure: There are not conflict of interest and source of founding